Venus Medtech (Hangzhou) Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VMTHF research report →
Companywww.venusmedtech.com
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries.
- CEO
- Hou-Sen Lim MEng.
- IPO
- 2021
- Employees
- 691
- HQ
- Hangzhou, CN
Price Chart
Valuation
- Market Cap
- $186.06M
- P/E
- -1.35
- P/S
- 1.81
- P/B
- 0.31
- EV/EBITDA
- -1.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 69.05%
- Op Margin
- -112.56%
- Net Margin
- -132.89%
- ROE
- -21.29%
- ROIC
- -14.88%
Growth & Income
- Revenue
- $298.87M · -36.52%
- Net Income
- $-397,172,134 · 44.40%
- EPS
- $-0.91 · 44.17%
- Op Income
- $-337,177,361
- FCF YoY
- -1764.03%
Performance & Tape
- 52W High
- $0.52
- 52W Low
- $0.25
- 50D MA
- $0.42
- 200D MA
- $0.37
- Beta
- 1.22
- Avg Volume
- 772.404
Get TickerSpark's AI analysis on VMTHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VMTHF Coverage
We haven't published any research on VMTHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VMTHF Report →